Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Donanemab (DHC12502)

Host species:Humanized
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHC12502

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50

Concentration

6.06 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P05067

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

LY3002813, CAS: 1931944-80-7

Clone ID

Donanemab

Data Image
  • SDS-PAGE
    SDS PAGE for Donanemab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Donanemab in Early Alzheimer's Disease, PMID: 33720637

Donanemab in Early Alzheimer's Disease, PMID: 34379933

Donanemab (LY3002813) dose-escalation study in Alzheimer's disease, PMID: 33614890

Donanemab in Early Alzheimer's Disease. Reply, PMID: 34379934

Brain volume loss due to donanemab, PMID: 34224184

Still grasping at straws: donanemab in Alzheimer's disease, PMID: 34162295

Critical Appraisal of Amyloid Lowering Agents in AD, PMID: 34110536

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression, PMID: 34198582

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering, PMID: 33971962

Datasheet

Document Download

Research Grade Donanemab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Donanemab [DHC12502]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only